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Yunis-Varo´n Syndrome Is Caused by Mutations
in FIG4, Encoding a Phosphoinositide Phosphatase
Philippe M. Campeau,1,15 Guy M. Lenk,2,15 James T. Lu,3,4 Yangjin Bae,1 Lindsay Burrage,1
Peter Turnpenny,5 Jorge Roma´n Corona-Rivera,6,7 Lucia Morandi,8 Marina Mora,8 Heiko Reutter,9
Anneke T. Vulto-van Silfhout,10 Laurence Faivre,11,12 Eric Haan,13 Richard A. Gibbs,3
Miriam H. Meisler,2,* and Brendan H. Lee1,14,*
Yunis-Varo´n syndrome (YVS) is an autosomal-recessive disorder with cleidocranial dysplasia, digital anomalies, and severe neurological
involvement. Enlarged vacuoles are found in neurons, muscle, and cartilage. By whole-exome sequencing, we identified frameshift and
missense mutations of FIG4 in affected individuals from three unrelated families. FIG4 encodes a phosphoinositide phosphatase
required for regulation of PI(3,5)P2 levels, and thus endosomal trafficking and autophagy. In a functional assay, both missense sub-
stitutions failed to correct the vacuolar phenotype of Fig4-null mouse fibroblasts. Homozygous Fig4-null mice exhibit features of
YVS, including neurodegeneration and enlarged vacuoles in neurons. We demonstrate that Fig4-null mice also have small skeletons
with reduced trabecular bone volume and cortical thickness and that cultured osteoblasts accumulate large vacuoles. Our findings
demonstrate that homozygosity or compound heterozygosity for null mutations of FIG4 is responsible for YVS, the most severe known
human phenotype caused by defective phosphoinositide metabolism. In contrast, in Charcot-Marie-Tooth disease type 4J (also caused
by FIG4 mutations), one of the FIG4 alleles is hypomorphic and disease is limited to the peripheral nervous system. This genotype-
phenotype correlation demonstrates that absence of FIG4 activity leads to central nervous system dysfunction and extensive skeletal
anomalies. Our results describe a role for PI(3,5)P2 signaling in skeletal development and maintenance.Yunis and Varo´n first described the syndrome that bears
their name in 1980, based on three Colombian families
with a total of five affected children.1 Since then, approxi-
mately 25 individuals with Yunis-Varo´n syndrome (YVS)
(MIM 216340) have been described.2–19 Frequent features
include structural brain abnormalities, sparse and pale
hair, and facial dysmorphisms. Skeletal abnormalities
include wide fontanelles with calvarial dysostosis, aplasia
or hypoplasia of the clavicles and phalanges in the hands
and feet, and absence of thumbs and halluces. Pelvic bone
dysplasia, absent sternal ossification centers, and fractures
are also frequent.17 Neuropathology shows extensive
neuronal loss and diffuse atrophy affecting the cerebellar
vermis, corpus callosum, basal ganglia, and frontal lobes.
Vacuoles compatible with enlarged lysosomes are seen in
neurons, muscle, cartilage, heart, and macrophages.17 In
theurine,multiple abnormal oligosaccharide bands appear,
suggesting a dysfunction of lysosomal enzymes,8,12 but no
consistent storage material could be identified12 and the
enzyme activities of oligosaccharidases were normal.8
Six families affected by Yunis-Varo´n syndrome were
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The Amaffected individuals are summarized in Table 1. Pictures
and radiographs of most affected individuals are available
in previously published case reports.5,7,8,18,20 The study
was conducted according to the guidelines of the institu-
tional review board of the Baylor College of Medicine
and informed consent was obtained prior to collection of
samples. The inclusion criterion was a high index of suspi-
cion of Yunis-Varo´n syndrome by a clinical geneticist.
Frequent features found in the individuals include sparse
scalp hair, protruding eyes, low-set ears, a high arched
palate, and micrognatia (Table 1). Skeletal features include
wide fontanelles and calvarial dysostosis, digital hypopla-
sia, especially of the thumbs and halluces, pelvic dysplasia
with hip dislocations, and absent or hypoplastic clavicles.
Affected individuals were significantly hypotonic and pre-
sented global developmental delay and often feeding and
swallowing difficulties. Central nervous system anomalies
in individuals 1 and 2 consisted of frontal lobe atrophy
with pachygyria and hypoplasia of the corpus callosum
and cerebellar vermis. In individual 3, autopsy revealed
an absent olfactory bulb and tract, an atypical ventricular
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Table 1. Clinical Features of Individuals Investigated
Individual Number
1 2 3 4 5 6 7 8
Review of the
Literature (n ¼ 17)
Familial relationship
and reference of first
description
affected siblings18 affected siblings5 first affected child8 first affected child20 first affected child,
unaffected brothers7
first affected child
Origin and consanguinity
in parents
Mexican,
third cousins
English,
nonconsanguineous
Italian,
nonconsanguineous
German,
nonconsanguineous
Anglo-Saxon,
nonconsanguineous
French,
nonconsanguineous
FIG4 mutations c.1260_1261delGT
(p.Thr422Glnfs*6)
from each parent
maternal mutation:
c.311G>A (p.Gly104Asp);
paternal mutation:
c.831_838delTAAATTTG
(p.Lys278Trpfs*6)
c.524T>C (p.Leu175Pro)
from each parent
no mutation by Sanger no mutation by
Sanger
no mutation by
Sanger
Gender F F M M F F M F
Age at last follow-up 1 year death at
2 months
death at
4 months
TOP death at 4 months 9 months death at 7 years after
cardiac surgery
1 month
Enlarged vacuoles
demonstrated on
pathological material
not on muscle
biopsy
NA þ (CNS) not on bone
histology
þ (muscle, CNS,
fibroblasts)
not on muscle biopsy NA NA
Birth weight (g) 2,200 2,470 3,030 250 at
18 weeks
2,580 3,035 2,630 3,250 2,397 5 298a
BW < 3rd percentile         10/17 (59%)
Birth length (cm) 45 46 52 24 at
18 weeks
47 51 44 49 46 5 2a
BL < 3rd percentile         10/14 (71%)
OFC (cm) 28 30 33 18 at
18 weeks
34 33 31 35 32 5 3a
Microcephaly þ þ     þ  9/16 (56%)
Head and Neck
Sparse scalp hair þ þ þ NA þ þ þ þ 17/17 (100%)
Wide fontanelle/sutures þ þ þ þ NA   þ 16/16 (100%)
Protruding eyes þ þ þ þ þ   þ 10/12 (83%)
Anteverted nostrils þ  þ þ þ  þ  12/13 (92%)
Short philtrum    NA þ    8/8 (100%)
Short upper lip þ þ þ þ þ þ  þ 13/13 (100%)
Labial-gingival retraction þ þ   þ  þ  8/10 (80%)
(Continued on next page)
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Table 1. Continued
Individual Number
1 2 3 4 5 6 7 8
Review of the
Literature (n ¼ 17)
High arched palate þ þ þ NA þ þ   9/10 (90%)
Micrognathia þ þ þ þ þ  þ þ 14/14 (100%)
Low set/dysplastic ears þ þ þ þ þ þ þ þ 18/18 (100%)
Loose skin in neck þ þ þ  NA þ þ þ 6/7 (86%)
Thorax
Congenital heart defect þ þ    þ þ þ 3/15 (20%)
Absent/hypoplastic nipples       þ  3/11 (27%)
Genital anomalies   þ    þ  5/13 (38%)
Limbs
Absent/hypoplastic
thumbs
þ þ þ þ þ  þ þ 16/17 (94%)
Short pointed fingers þ þ þ þ þ  þ þ 14/15 (93%)
Absent/hypoplastic
halluces
þ þ þ þ þ   þ 16/16 (100%)
Short pointed toes þ þ þ þ þ þ þ þ 15/16 (94%)
Absent/hypoplastic nails þ þ þ þ þ þ þ þ 12/14 (86%)
Single palmar crease þ þ þ þ NA  þ  5/7 (71%)
Central Nervous System
Structural brain
anomalies (see text)
þ þ þ þ þ þ þ  6/12 (50%)
Hypotonia þ þ þ NA þ þ þ þ 5/5 (100%)
Radiological
Calvarial dysostosis þ þ þ þ NA NA   15/15 (100%)
Craniofacial
disproportion
þ þ þ þ NA    8/8 (100%)
Absent/hypoplastic
clavicles
þ þ   NA  þ  13/17 (76%)
Absent sternal
ossification center
þ þ NA NA NA    7/7 (100%)
Pelvic dysplasia þ þ þ  NA  þ þ 9/10 (90%)
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784 The American Journal of Human Genetics 92, 781–791, May 2, 23 and 5 of the cerebral cortex, the cerebellar dentate
nucleus, and the olivary bodies. Individual 4 had agenesis
of the corpus callosum, and individual 5 had neuronal loss
with vacuolation in the cerebral cortex, the thalamus,
subthalamic nuclei, globus pallidus, and the cerebellar
dentate nucleus. Investigations for peripheral neuropa-
thies had not been performed in part because of the
absence of suggestive clinical findings, a fact that might
be confounded by the severe central neurological disease
in these individuals and the frequent early death. At the
autopsy of individual 3, muscle histology was compatible
with neurogenic atrophy. Electron microscopy of skin
fibroblasts from individual 5 revealed the presence of large
vacuoles as well as electron-dense inclusions (Figure 1A).
Histological examination of muscle revealed variable fiber
size and large vacuoles in many fibers (Figures 1B–1D).
Electron microscopy of muscle detected membrane-
limited vacuoles derived from sarcolemma and myofibrils,
filled with amorphous, granular, or membranous material
and partially degraded organelles (Figures 1E and 1F).
Most vacuoles were membrane limited, with those at the
fiber surface also limited by the basal lamina. Mito-
chondria were normal in size, number, and morphology.
Candidate gene analysis for RUNX2, mutations in which
cause classical cleidocranial dysplasia (MIM 119600), failed
to detect mutations.22 Exome sequencing was performed
as described previously23,24 on individuals 1 and 5 and
the parents of individuals 3 and 4 because high-quality
DNA required for exome sequencing was not available
from individuals 3 and 4. Sequence analysis of genes
with rare (MAF < 1%) or novel mutations yielded FIG4
(RefSeq accession number NM_014845.5) as the best
candidate because the spontaneous Fig4-null mouse has
multiple related phenotypes including cellular vacuola-
tion, neurodegeneration, and dysplasia of the corpus cal-
losum.25 The FIG4 genotypes of parents and affected
offspring in the three families described in Table 1 are
shown in Figure 2. In family 1, the parents were third
cousins and both were carriers of the same 2 bp frameshift
deletion, c.1260_1261delGT, which is predicted to cause
protein truncation upstream of the phosphatase catalytic
motif CX5RT/S (Figure 3A) and therefore complete loss of
function. In family 2, the maternal allele was the missense
variant p.Gly104Asp (c.311G>A) and the paternal allele
was an 8 bp frameshift deletion (c.831_838delTAAATTTG).
After identification of heterozygous mutations in the
parents, a pathology specimen demonstrated inheritance
of both mutations in individual 3. In family 3, with no
reported consanguinity, both parents were heterozygous
for the novel missense variant p.Leu175Pro (c.524T>C)
and the affected child was homozygous for the variant
allele. The missense substitutions in individual 1
(Gly104Asp) and individual 5 (p.Leu175Pro) alter amino
acid residues that are highly conserved through evolution
(Figure 3B). Glycine 104 is located at the beginning of b
sheet 7 within the noncatalytic, protein-binding domain
of FIG4 (Figure 3C).27 Leucine 175 is located in a helix 2013
Figure 1. Abnormal Subcellular Morphology in YVS Tissues
(A) Electron micrograph of cultured skin fibroblasts from indi-
vidual 5 showing large, empty cytoplasmic vacuoles and elec-
tron-dense inclusion bodies. Scale bar represents 1 mm.
(B–D)Muscle sections stained with Gomori trichrome (B), Periodic
Acid Schiff (PAS) (C), and acid phosphatase (D) reveal variable fiber
size and large vacuoles containing basophilic material stained by
acid phosphatase and PAS staining. Scale bars represent 10 mm.
(E and F) Electron micrographs of skeletal muscle showing
vacuoles in the subsarcolemmal (E) and intramyofibrillar (F)
spaces filled with amorphous, granular, or membranous material
and partially degraded organelles. The vacuoles are mostly mem-
brane limited; those located at the fiber surface abutting the
extracellular space are also limited by the basal lamina (arrow-
heads). The mitochondria were normal in number, size, and
morphology (inset). Scale bars represent 1 mm.
Figure 2. Segregation of FIG4 Mutations in Three Unrelated
YVS-Affected Families
FIG4 genotypes of family members demonstrating autosomal-
recessive inheritance with sequencing chromatograms below.
Numbering from RefSeq NM_014845.5.of the same domain and appears to interact directly with
residue Glu302, the site of a functionally null substitution
in a individual with CMT4J26 (Figure 3C). Four protein
prediction programs assessed these two missense
variants as likely to affect FIG4 function (Table S1 available
online).
We developed a functional assay for FIG4 activity based
on rescue of the cytoplasmic vacuolization seen in
cultured fibroblasts from the Fig4-null mouse.25,28 Null fi-
broblasts are transfected with Fig4 cDNA plus GFP cDNA
to permit identification of successfully transfected cells
by their fluorescence. Representative transfected cells are
shown in Figure 4A. The wild-type Fig4 cDNA rescued
vacuolization in 73% of transfected cells, whereas the
p.Gly104Asp and p.Leu175Pro mutant cDNAs failed to
correct vacuolization (Figure 4B). Comparable levels of
expression were obtained with the different transgenes
(see Figure S1). The complete lack of rescue in this assayThe Amindicates that p.Gly104Asp and p.Leu175Pro are loss-of-
function, null substitutions.
Sanger sequencing in affected individuals from three
additional families did not detect FIG4 mutations. Some
of these individuals did not present with all the classical
clinical features of Yunis-Varo´n syndrome (see Table 1 for
details). Apart from the presence of calvarial dysostosis,
no other feature distinguished the individuals with FIG4
mutations from those without. There was a trend toward
a higher number of features in individuals with FIG4
mutations (Table 1, bottom row). The individuals without
identified FIG4 mutations might carry undetected muta-
tions within introns or regulatory elements of FIG4.
Alternatively, Yunis-Varo´n syndrome may be genetically
heterogeneous with some cases caused by mutations in
other gene(s).
FIG4 encodes a lipid phosphatase that is part of a
multiprotein complex regulating the abundance of the
signaling phosphoinositide PI(3,5)P2.
29,30 The protein
complex, which is localized on the membranes of late
endosomes and lysosomes, also contains the kinase
PIKfyve/FAB1 that converts PI(3)P to PI(3,5)P2 and the
scaffold protein VAC14. The transient production of
PI(3,5)P2 at the cytoplasmic surface of intracellular vesicles
is thought to mediate vesicle fusion and trafficking via
interaction with effector proteins such as WIPI1.31 Defi-
ciency of FIG4 results in instability of the biosynthetic
complex, reduced PI(3,5)P2 concentration, and accumula-
tion of enlarged intracellular vacuoles containing the
lysosomal membrane proteins LAMP1 and LAMP2.25,32,33
The pale tremor mouse carries a spontaneous null muta-
tion of Fig4 caused by a retroposon insertion that results
in loss of Fig4 mRNA25 and protein.28 Fig4-null mice have
small body size, diluted hair color, spongiform degenera-
tion of the central and peripheral nervous systems, and ju-
venile lethality.25 This phenotype is recapitulated by global
deletion of the floxed Fig4 allele.34 Fig4 is expressed ubiqui-
tously and in the brain the highest expression is in hippo-
campus, striatum, and hindbrain.35 Neurodegeneration inerican Journal of Human Genetics 92, 781–791, May 2, 2013 785
AB C
Figure 3. Location of FIG4 Mutations
(A) Location of mutations in FIG4 exons;
introns not drawn to scale. Above, YVS;
below, CMT4J.26 Protein-interaction do-
main, blue; catalytic domain, yellow;
P loop containing the catalytic CX5R(T/S)
motif, orange.
(B) Evolutionary conservation of amino
acids around the missense mutations.
Alignmentwas performedwith ClustalW2.
Dots represent identity; dashes represent
gaps.
(C) Positions of substitutions in the
3-dimensional protein structure (courtesy
of Yuxin Mao27). Same color scheme as in
(A). Abbreviations used to designate amino
acids are as follows: G104, p.Gly104; L175,
p.Leu175; S176, p.Ser176; S320, p.Ser320;
E302, p.Glu302; and R274, p.Arg274.
Gly104 is located at the beginning of b sheet
7 within the noncatalytic, protein-binding
domain of FIG4.27 p.Leu175 is located in a
helix 2 of the same domain and appears to
interact directly with residue p.Glu302,
the site of a functionally null mutation
in an individual with CMT4J.26 GenBank
transcript used for FIG4 residue num-
bering was NM_014845.5. The NCBI pro-
tein sequences used for alignment were
as follows: human, accession number
NP_055660.1; mouse, NP_598760.1; rat,
NP_001040561.1; dog, NP_001108097.1;
cow, NP_001069482.1; chicken,
NP_001108095.1; Fugu, CAG03571.1;
Ciona intestinalis, XP_002125633.1; and
yeast Saccharomyces cerevisiae, NP_014074.1.Fig4-null mice is most pronounced in layers 4 and 5 of the
cortex, brain stem, and deep cerebellar nucleus and pro-
gresses from accumulation of large intracellular vacuoles
to extensive spongiform degeneration. Inclusion bodies
containing p62 and LAMP1 accumulate in astrocytes of
Fig4-null mice, apparently as a result of impaired
resolution of autophagolysosomes.25,32,36 Deficiency of
FIG4 also results in defective myelination of the central
and peripheral nervous systems and hypoplasia of the
corpus callosum.25,32,37 Neuron-specific expression of a
Fig4 transgene in the null mice substantially rescues
neurodegeneration, myelination, and survival, and the
neuron-specific knockout recapitulates the null pheno-
type.34
Mutations of human FIG4 were previously identified in
individuals with Charcot-Marie-Tooth disease type 4J
(MIM 611228), an autosomal-recessive peripheral neu-
ropathy that progresses to wheelchair dependence and
death.25,26 Individuals with CMT4J are compound hetero-
zygotes carrying one null mutation and one missense
substitution. All but one CMT4J individual carry the
missense substitution Ile41Thr,26 which reduces binding
affinity for the scaffold protein VAC1428 and destabilizes
the protein.28,38 Overexpression of FIG4-Ile41Thr in trans-
genic mice can rescue the null phenotype,28 and the
mutant protein retains activity in a yeast vacuolization
assay,39 demonstrating that this variant retains partial786 The American Journal of Human Genetics 92, 781–791, May 2, 2function. In contrast, the more severe Yunis-Varo´n
phenotype is the result of complete loss of FIG4 activity.
The striking differences between Yunis-Varo´n and
CMT4J provide a clear example of diverse clinical conse-
quences resulting from different allelic mutations of the
same gene.
The clinical effects of heterozygous FIG4 mutations
remain unclear. We previously described heterozygous
null mutations in amyotrophic lateral sclerosis (ALS).39
However, two smaller studies of ALS did not detect muta-
tions.40,41 Further, heterozygous null parents in CMT4J
pedigrees do not report symptoms of motor neuron dis-
ease.25,26 Heterozygosity for FIG4-null mutations may
constitute a risk factor or modifier of neurological disease
rather than an independent cause.
Skeletal dysplasia is a consistent feature of YVS not
previously investigated in the Fig4-null mouse. Animal
experimentation was performed under approval from the
Institutional Animal Care and Use Committee of the
University of Michigan. We assessed Fig4 expression in
wild-type mouse tissues and found that expression in
calvaria, osteoblasts, and bone marrow cells is comparable
to expression in brain (Figure S2). We previously described
in detail the neuropathology found in Fig4-null mice, but
we did not investigate skeletal phenotypes. Unlike individ-
uals with YVS, Fig4-null mice do not exhibit aplasia or hy-
poplasia of digits on the front or rear limb (Figure S3A).013
Figure 4. Functional Effects of FIG4 Mu-
tations
Transfection assay for FIG4 function. Low-
passage (<7) embryonic fibroblasts from
E13 homozygous Fig4/ mice (MEFs)
were cotransfected with 6 mg GFP cDNA
and 6 mg of the indicated Fig4 cDNA via
Fugene-6 (Promega). The presence of
vacuoles in fluorescent cells was assessed
with an inverted Leica DMIRB microscope
equipped with epifluorescence and an
Olympus DP30 BW digital camera. Fluo-
rescent cells were classified as vacuolated
if they contained R6 vacuoles. Represen-
tative transfected cells are shown in (A)
(GFP on the left). The percent of trans-
fected (fluorescent) cells lacking vacuoles
resulting from correction by the trans-
fected Fig4 cDNA is shown in (B), with
the number of nonvacuolated cells and
the total number of cells assayed.Homozygous null animals have reduced body weight and
impaired growth (Figure S3B). The skeleton is normal at
birth but is noticeably smaller at postnatal day 21 (P21),
when long bones and clavicles are 20%–25% smaller
than those of wild-type littermates (see Figure S3C for
femoral length). Normal shape of the clavicles and pelvic
bones were demonstrated in newborn mice and in dissec-
tions and 3D reconstructions frommicrocomputed tomog-
raphy (microCT) of mice at P21 (Figure 5). Although the
bones were normally shaped and had a normal external
appearance, they had an obvious lower trabecular and
cortical density, as can be observed by the porous appear-
ance in 3D reconstructions with a density thresholding
adequate for wild-type mouse skeletons (Figure 5). To
investigate trabecular and cortical bone density in a quan-The Amtitative manner, we carried out microCT of vertebrae and
femurs at P21 (Figure 6) as described previously.42 The
reduced size and density of the trabeculae is evident in
the vertebral cross-section (Figures 6A and 6B). Bone
volume fraction, bone surface, trabecular number, and
connectivity density were reduced to less than 50% of
wild-type values, whereas trabecular separation was
increased more than 3-fold (Figures 6C–6H). Moreover,
femoral cortical thickness was reduced to less than 50%
of wild-type values (Figures 6J and 6K). Extensive vacuoli-
zation was observed in cultures of isolated osteoblasts
from calvarial tissue (Figure 6L), isolated as described
previously,43 and in cultured bone marrow mesenchymal
stromal (not shown). The analysis of skeletal development
in Fig4-null mice thus demonstrates abnormal ossificationFigure 5. 3D Reconstruction after
MicroCT Scanning of Mouse Skeletons
Developmental defects of the skeletons are
not present in Fig4-null mice (age P21).
Multiple views are provided for the
cranium, clavicles, and pelvis.
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Figure 6. MicroCT Analysis of Fig4-Null
Mice
(A) 3D reconstruction of L4 vertebrae of
P21 littermates.
(B) Trabecular bone of L4 vertebrae.
(C–K) MicroCT analysis of L4 vertebral
bone. Bone volume fraction, BV/TV (C);
bone surface, BS (D); trabecular number,
Tb.N (E); trabecular thickness, Tb.Th (F);
trabecular separation, Tb.Sp (G); connec-
tivity density, Conn.D (H); density of
trabecular bone, Density of BV (I).
(J) 3D reconstruction of femurs of P21
littermates, with a cut plane through the
third trochanter.
(K) Femoral cortical thickness, from below
the third trochanter to the middiaphysis.
n ¼ 4 per group for the vertebrae and
femurs; *p < 0.05.
(L) Vacuolization is clearly seen in cultured
primary osteoblasts from Fig4-null mice.
All errors bars represent standard
deviation.and vacuolized osteoblasts. A comparison of the pheno-
types in humans and mice is given in Table 2.
In addition to Charcot-Marie-Tooth disease (FIG4 and
MTMR2 genes), defects of phosphoinositide metabolism
can result in a wide variety of conditions as listed in Table
S2.44–46 Opsismodysplasia (MIM 258480) was recently
identified to be caused by defects in the inositol-1,4,5-tri-
sphosphate 5-phosphatase INPPL1.47,48 Although clearly
different from YVS notably because of the rhizomelia, pla-
tyspondyly, and frontal bossing in opsismodysplasia, there
are overlapping clinical features such as a large anterior
fontanelle, anteverted nostrils, pelvic bone anomalies,
metaphyseal anomalies (cupping in opsismodysplasia, flar-
ing in YVS), delayed ossification, shortened digits, hypoto-
nia, and early death.
Calvarial and clavicular development is most dependent
on intramembranous bone formation, yet endochondral
ossification is also involved in clavicular development.49
Abnormal formation of the clavicles and cranial vault in788 The American Journal of Human Genetics 92, 781–791, May 2, 2013humans is observed in cleidocranial
dysplasia resulting from mutations
of RUNX2, a transcription factor
critical for both intramembranous
and endochondroal ossification of
the skeleton, and also in several other
syndromes (Table S3). In view of the
abnormal development of cranium,
clavicles, pelvic bones, digits, and
sternal ossification in humans and
the low bone mass in mice, it is likely
that FIG4 deficiency affects membra-
nous ossification and endochondral
ossification as well as skeletal mainte-
nance. The report of abnormal ossifi-
cation and increased markers of
bone turnover in YVS12 suggest anunderlying imbalance of bone formation and resorption
that may result from intrinsic defects of both osteoblasts
and osteoclasts. Future investigation of vesicular traf-
ficking and autophagy in mice with conditional knockout
in specific lineages will permit identification of the
stages of skeletal development and maintenance that
require FIG4.
Supplemental Data
Supplemental Data include three figures and four tables and can
be found with this article online at http://www.cell.com/AJHG/.
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